Specialty Pharmacy

Multiple myeloma disease development affected by pituitary tumor transforming gene.

Cheryl Allen, RPh, BSPharm, MBA, vice president of Industry Relations at Diplomat, discusses how relationships can be improved between manufacturers, pharmacy benefit managers, and pharmacies.

Research may improve the diagnosis of infectious and autoimmune diseases, including rheumatoid arthritis and HIV.

Research may minimize operations for benign disease while maintaining a low morbidity and mortality for surgical resection.

Researchers seek to improve diagnosis, support genetic counseling, and enhance medical management.

Treatment doubles overall survival of patients with recurrent glioblastoma.

Injection drug use most frequently linked to a positive hepatitis C screening.

Process makes tumors more sensitive to chemotherapy to improve targeted therapy.

Top news of the week in cancer drug development.

Process can improve medical care with better results for patients.

Research may offer powerful new tool in the treatment of HIV.

Top stories of the week on Specialty Pharmacy Times.

Certain pesticide contaminants found to increase risk of multiple myeloma.

Chronic hepatitis C infection linked to the prevalence of plaque and noncalcified plaque in the arteries.

App could improve cancer diagnostics in low- to middle-income and remote areas.

Study determines which genetic mutations in cancer will be most likely to respond to chemotherapy.

Rural and cancer hospitals will no longer have access to 340B discount pricing for orphan drug purchases.

The FDA today has granted accelerated approval to Boehringer Ingelheim's intravenous solution idarucizumab (Praxbind) for the rapid reversal of Pradaxa.

Synjardy, a type 2 diabetes treatment, is now available by prescription in US pharmacies.

High-dose chemotherapy and autologous stem cell transplantation show promise for patients with light-chain amyloidosis.

Processing speed linked to both activity and participation among patients with MS.

Many colon cancer disparities found in patients of different races under 50-years old.

Secukinumab shows promise in the treatment of patients with psoriatic arthritis.

Carcinoid syndrome frequently prevents patients from leading active lives.

RA patients carry myocardial and vascular abnormalities even in the earlier stages of disease progression.

Dinaciclib may be able to eliminate metastases without shrinking the primary tumor.

Recall affects products that were compounded prior to September 1, 2015.

A generic version of Avodart, used to treat the symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate, has been launched by Teva Pharmaceutical Industries Ltd.